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The nontuberculous mycobacteria (NTM) comprise a  large group of micro- 
organisms  that  are  rarely  associated with  disease in  humans.  This  situation  is 
rapidly  changing,  however,  as  substantial  numbers  of patients  with  Acquired 
Immune Deficiency Syndrome (AIDS) are now being diagnosed as infected with 
members of the Mycobacterium  avium complex (1, 2).  To date, however, little is 
known concerning the precise nature of the protective cellular response to this 
class of mycobacterial infections, either in humans or in experimental models in 
the  mouse (3-5).  A  fundamental  question  that  arises  concerning  the  possible 
development of effective vaccines against NTM is the problem of whether species- 
specific antigens are important in the generation of protective immunity to each 
of the  NTM  infections, or whether this can be achieved by the recognition of 
common antigens expressed by most or all mycobacterial strains. 
The  purpose of this  study, therefore,  was to determine whether immune  T 
cells, acquired  in  response to intravenous  infection  with M.  tuberculosis,  could 
recognize antigens (protective antigens) associated with a variety of NTM infec- 
tions and thus give rise to a  protective cellular response.  In these experiments, 
memory immune  T  cells were used as the effector T  cell population  so as to 
overcome a  number of technical problems. The first consisted of the fact that 
actively immune T cells, generated during the early stages of the primary immune 
response to tuberculosis infection, are functionally short lived (I. Orme,  manu- 
script submitted for publication), and thus would not be expected to survive long 
enough to give rise to a  state of immunity after passive transfer into recipients 
infected with NTM; NTM infection sometimes can take up to 1-3 mo to grow 
to an immunogeneic  threshold  (6).  Also, to prevent the possibility of contami- 
nating viable M. tuberculosis being transferred in the cell inoculum (7) and actively 
immunizing the recipient so that any observed effects on the NTM test infection 
might be the result of increased nonspecific resistance (8), donor mice were given 
a protracted course of isoniazid chemotherapy to eliminate viable M. tuberculosis 
and thus give rise to a state of memory immunity (9) in these animals. 
Our results provide evidence that strongly support the hypothesis that relevant 
protective antigens expressed by NTM infections can be recognized by memory 
immune protective T  cells that have been acquired in response to M. tuberculosis 
infection,  thus suggesting that  these protective antigens are common,  or suffi- 
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ciently  crossreactive  to  give  rise  to  the  generation  of  a  protective  cellular 
response. 
Materials and  Methods 
Mice.  These experiments were performed using specific pathogen-free male C57BL/6 
mice 6-8 wk old. These animals were provided by the Trudeau Animal Breeding Facility. 
Bacteria.  M. tuberculosis (strain Erdman; Trudeau Mycobacterium Collection [TMC] 
107),  M.  simiae  (N29;  TMC  1226),  M.  avium  (3459-1-T;  TMC  724),  and M.  kansasii 
(Brownell; TMC 1203), were grown under conventional conditions previously described 
(10). 
Experimental  Infections.  Stored  frozen  ampoules  of bacteria  were  thawed,  briefly 
sonicated,  and  diluted  to  the  required  inoculum  size  in  cold  sterile  PBS.  Mice  were 
infected intravenously with an inoculum of 0.2 ml of the bacterial suspension via a lateral 
tail vein. 
Mice  were exposed  to airborne  infections  using a  Middlebrook  Airborne  Infection 
Apparatus (Tri-R Instruments, Inc., Rockville Centre, NY). The nebulizer compartment 
was filled with inocula of bacteria adjusted to concentrations calibrated to deliver an acute 
infectious dose (~104 viable bacteria) into the lungs over a 30 rain exposure period (7). 
The course of experimental infections was followed against  time by sacrificing 4-5 
animals and  plating serial  dilutions  of individual  whole  target organ  homogenates on 
nutrient Middlebrook 7H 11 agar (Difco Laboratories, Detroit, MI) and counting bacterial 
colony formation after 14-20 d incubation at 37°C. 
Passive Cell Transfers.  Groups of donor animals were infected intravenously with 10 s 
M. tuberculosis Erdman. One group of mice was infected with 107 heat-killed M. tuberculosis 
as an additional control.  25 d  later,  mice were exposed to  200  mg/liter isoniazid (iso- 
nicotinic acid hydrazide; Pfizer Co.,  NY) in their drinking water. After 60 d  more, the 
numbers of viable bacteria in the target organs of these mice had fallen below levels of 
detectability, and the animals were sacrificed and spleen cells were harvested. These cells 
were suspended in RPMI 1640 tissue culture medium supplemented with 1 mM glutamine 
and 2% heat-inactivated FCS, and then enriched for T  cells by the procedure of Mage et 
al. (1 I), which depletes B cells by adherence to plastic dishes coated with antisera against 
mouse Ig. In some experiments, these cells were then treated with anti-Thy-l.2 mAb plus 
complement, as previously described (7).  One spleen equivalent of memory immune T 
cell-enriched spleen cells were then intravenously transferred into age- and sex-matched 
syngeneic recipients that had been rendered T  ceil-deficient by exposure to 500 rad of 
gamma irradiation before the transfer (7). Control mice were infused with normal T  cell- 
enriched spleen cells. To exclude the possibility that a few viable M. tuberculosis organisms 
had escaped the effects of isoniazid therapy in tbe donor animals, recipient mice were 
started on isoniazid 7 d before the transfer, and for 7 d after transfer. After this time, a 
few recipient  mice were  further  checked  for  the  presence  of viable  mycobacteria by 
treatment with cortisone acetate (9) followed by plating of target organs  14 d  later; all 
mice were negative for the presence of active infection. 
14 d after the passive transfer of memory immune T  cells, test and control mice were 
challenged via intravenous or aerogenic routes with the various mycobacterial infections, 
and the courses of these infections were followed against time in target organs as above. 
Results 
Efficacy of Isoniazid  Chemotherapy.  In initial experiments, recipient mice that 
had received spleen cell inocula from isoniazid-treated donor mice were checl~ed 
for the presence of possible contaminating viable M.  tuberculosis organisms; this 
was performed in view of the earlier observation (9) that a  few residual bacteria 
can often survive this type of chemotherapy. We found (Table I) that if recipient 
animals  were  not  treated  with  isoniazid,  a  small  but  potentially  immunizing ORME  AND  COLLINS  BRIEF  DEFINITIVE  REPORT  205 
TABLE  I 
Efficacy of lsoniazid Chemotherapy 
Chemotherapy given 
lsoniazid  Cortisone* 
Iogt0 bacteria in spleens on day 14' 
-  -  3.01  _+ 0.08 
-  +  3.86 --+ 0.33 
+  -  <1.00 
+  +  <1.00 
* Mice were injected subcutaneously with 20 mg/kg cortisone acetate daily for 14 
d. 
* Mean numbers of bacteria recovered + SEM (n =  4). 
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FIGURE  1.  The growth of four intravenous mycobacterial challenge infections in the spleens 
(top) and livers (bottom) of T  cell-deficient mice adoptively immunized with M.  tuberculosis- 
specific  memory immune T  cell-enriched  spleen  cells.  The  data  shows the  course  of the 
challenge infection in recipients given memory immune cells (["1), normal cells (Q), or immune 
cells treated with anti-Thy-l.2 mAb plus complement (&), or with complement alone (O). In 
addition (right),  some donor mice received heat-killed M.  tuberculosis (T) instead of the living 
organism. Data is expressed as the mean number of bacteria in target organs (n =  4-5); SEM 
is omitted; it never exceeded 0.24. 
number of viable M.  tuberculosis  could be recovered from the spleens of these 
animals 14 d later. Based upon our previous experience with this organism, the 
numbers  of bacteria  recovered after  this  period  probably  reflected ~10-50 
viable bacteria originally present in the transferred inoculum. 
Treatment of similar groups of recipient mice with isoniazid destroyed contam- 
inating bacteria to below levels of detectability (Table I). The effectiveness of 
this treatment was further shown by a failure to detect viable bacteria in these 
animals following continued injection with cortisone acetate. Thus, although it 
was clear that a  few viable bacteria were originally present in the transferred 
spleen cell inocula, the possibility that these organisms survived in the isoniazid- 
treated recipients,  thus actively immunizing these recipients, was regarded as 
unlikely. 
Passive  Transfer of Protection  Against Intravenous NTM Infections.  Adoptively 
immunized recipients were substantially more resistant than controls to intrave- 
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FIGURE 2.  The growth of the four test mycobacterial challenge infections in the lungs of 
adoptively immunized  (O) and  control  mice given normal  T  cells (0)  following aerogenic 
deposition  of-104  mycobacteria.  Mice infused  with  normal  cells and  challenged  with M. 
tuberculosis (right) died by day 25. Data expressed as mean values (n -- 4-5); SEM is omitted; 
it never exceeded 0.22. 
a  slower  rate  of progressive  growth  of the  infection  in  the  spleen,  and  its 
containment,  without  detectable  proliferation,  in  the  liver.  Evidence  for  the 
generation of a protective cellular response was also observed against the three 
NTM infections, although  its effect on the course of each infection differed. In 
the case of M.  simiae, proliferation  was completely prevented,  thus resulting in 
an  apparent  bacteriostasis.  In  contrast,  there  was  evidence  for  the  slow  but 
progressive  elimination  of the M.  kansasii  infection,  while  the  third  infection 
under  test, M.  avium,  grew  rapidly in  the  spleens and  livers of the  adoptively 
immunized animals before showing some evidence of slowing after day 30 of the 
experiment. 
In each  infection,  the protective effect of the passively transferred  memory 
immune spleen ceils was mediated by T  cells, as evidenced by the observation 
that the protective effect was ablated by prior treatment of transferred cells with 
anti-Thy-l.2  mAb  plus  complement,  but  not  by complement  alone  (Fig.  1). 
Finally,  as an  additional  control,  recipients  that  had  received T  cell-enriched 
spleen  cells  from  donor  mice  that  had  been  injected  with  107  heat-killed  M. 
tuberculosis  were shown  to possess no  enhanced  resistance  to  the  homologous 
viable challenge infection, thus indicating that dead mycobacteria that might be 
present in the transferred cell inoculum had no immunizing capacity. 
Passive  Transfer of Protection Against Airborne NTM Infections.  In  a  parallel 
series of experiments,  the capacity of adoptively immunized recipients to resist 
airborne infection with each  NTM  was determined.  We found (Fig.  2) that,  in 
three experimental infections (M.  tuberculosis, M. kansasii, and M. avium), recip- 
ients that had received memory immune T  cells were able to express significantly 
enhanced  resistance  to these challenge  infections, although  it was clear that  in 
each case this resistance was expressed somewhat more slowly in the lungs than 
to the intravenous  challenge.  In the case of M.  simiae,  however, this  organism 
was slowly cleared from the lungs of control animals, and there was no evidence 
of any acceleration of this process in the adoptively immunized mice. 
Discussion 
The  results  of this  study  show  that  the  adoptive  immunization  of T  cell- 
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immune T-enriched spleen cells can confer upon that recipient the capacity to 
express enhanced  resistance  to both a  homologous challenge and to challenge 
with three representative NTM infections, M. simiae, M. avium, and M. kansasii. 
Prior treatment with anti-Thy-l.2  mAb plus complement ablated this protective 
effect, thus formally showing that it was mediated by T  lymphocytes. 
The results of the study thus support the hypothesis that the antigenic deter- 
minants  expressed  by  these  three  NTM  infections  which  will  give  rise  to  a 
protective cellular response to the homologous organism, are identical or closely 
crossreactive to epitopes that are recognized by M. tuberculosis-specific memory 
immune T  cells. These observations, therefore, may help to explain the mecha- 
nism by which M. boris BCG vaccination can be effective against NTM infections 
(12),  which  presumably  reflects  another  example  of cross-protective  specific 
immunity. 
The nature of the protective antigens that give rise to cellular immunity to M. 
tuberculosis and  the  NTM  infections,  however,  remains totally unknown.  The 
effective  generation  of protective  immunity  to  these  organisms  requires  the 
presence  of living  bacteria,  and,  while  heat-killed  mycobacteria may,  in  some 
situations, increase the nonspecific resistance of the host, no formal evidence for 
the generation  of protective T  cells in this latter case is currently available.  In 
view of this, it is tempting to speculate that the protective antigens that appear 
to be common to the immunogenic  mycobacteria may be metabolites that  are 
produced  by  the  living  proliferating  organism,  rather  than  being  structural 
antigens. 
Summary 
Adoptive immunization of T  cell-deficient recipient mice with M. tuberculosis- 
specific memory immune T  lymphocytes conferred upon these animals the ability 
to express significantly enhanced  resistance  both to the homologous infection, 
and to three strains of nontuberculous mycobacteria. These results support the 
hypothesis, therefore, that antigenic  determinants  possessed by the four myco- 
bacterial strains that are relevant to the generation of protective cellular immu- 
nity are identical or closely crossreactive. 
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